ConnectiveRx has launched ShieldRx, a new pharmacy monitoring and misuse prevention engine, developed in partnership with EagleForce, to identify and stop suspect pharmacy activity before payment, thereby safeguarding gross-to-net performance for branded and specialty medications.
Manufacturers face increasing pressure on gross-to-net performance due to payer tactics, accumulator and maximizer programs, and growing pharmacy misuse. Traditional post-pay audits and retrospective controls are often insufficient to address these challenges. ShieldRx provides proactive, in-workflow protection designed to identify and stop suspect activity before claims are paid.
The latest addition to ConnectiveRx’s Gross-to-Net Protection platform, ShieldRx integrates ConnectiveRx’s expertise in affordability program design and real-time adjudication with EagleForce’s advanced identity, compliance, and transaction-level intelligence. This collaboration aims to deliver a fully integrated pharmacy misuse prevention solution embedded directly into the pharmacy workflow.
Pharmacy misuse and invalid copay behavior contribute to an estimated $5 billion in manufacturer revenue loss annually. ShieldRx addresses this issue through several key features: AI-driven risk models trained on large-scale pharmacy, patient, prescriber, and historical claims data to identify statistically abnormal behavior; real-time, in-workflow risk scoring that pinpoints suspect transactions before payment; high-speed claim evaluation delivering pass/fail decisions in seconds; and a pharmacist-accessible resolution center for immediate follow-up, verification, and documentation.
By intercepting and preventing invalid activity in real time, ShieldRx allows manufacturers to protect copay investments, strengthen program integrity, and ensure affordability funds are used as intended. The solution deploys seamlessly within existing pharmacy workflows.
Cindy Baksh, Chief Product Officer at ConnectiveRx, stated, “Manufacturers are under unprecedented pressure to protect gross-to-net performance without disrupting patient access. ShieldRx sets a new standard for proactive oversight, giving brands real-time protection, clearer insight, and greater confidence in the integrity of every claim.”
Stanley Campbell, Jr., Chief Executive Officer at EagleForce, commented, “ShieldRx represents a game-changing advancement in how manufacturers protect gross-to-net. By combining EagleForce’s real-time identity and transaction intelligence with ConnectiveRx’s embedded pharmacy workflows and scale, manufacturers can identify and stop suspect behavior in seconds, before payment, without disrupting legitimate patient access.”
Pilot implementations across high-volume brands have demonstrated detection performance, operational readiness, and strong return on investment.
ConnectiveRx is a technology-enabled pharmaceutical services company that provides patient and provider support, access, and adherence solutions for specialty and branded medications. In 2025, McKinsey & Company independently ranked ConnectiveRx #1 in copay services and highest in Net Promoter Score across the patient support services landscape. Its solutions include a patient engagement and access platform (hub services), patient and provider adherence messaging, patient affordability programs, and the Prescribers’ Digital Reference.
EagleForce Health specializes in healthcare analytics, offering real-time intelligence and compliance-focused solutions that support informed access, program integrity, and regulatory oversight across the pharmaceutical and healthcare sectors.
